Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2017

Open Access 01-12-2017 | Original Article

Androgen Signaling in Esophageal Adenocarcinoma Cell Lines In Vitro

Authors: Helen M. Palethorpe, Paul A. Drew, Eric Smith

Published in: Digestive Diseases and Sciences | Issue 12/2017

Login to get access

Abstract

Background

We showed previously that nuclear localization of the androgen receptor (AR) and expression of the androgen-responsive gene FK506-binding protein 5 (FKBP5) in esophageal adenocarcinoma (EAC) tissues were associated with decreased patient survival, suggesting a role for androgens in this cancer.

Aim

To investigate the effect of the AR ligand 5α-dihydrotestosterone (DHT) on AR-expressing EAC cell lines in vitro.

Methods and Results

In tissue resection specimens from EAC patients, FKBP5 expression was positively associated with proliferation as measured by Ki-67 expression. We stably transduced AR into three AR-negative EAC cell lines, OE33, JH-EsoAd1, and OE19, to investigate androgen signaling in vitro. In the AR-expressing cell lines, 10 nM DHT, the concentration typically used to study AR signaling, induced changes in the expression of androgen-responsive genes and inhibited proliferation by inducing cell cycle arrest and senescence. At lower DHT concentrations near the half maximal inhibitory concentration (IC50), the AR-expressing cell lines proliferated and there were changes in the expression of androgen-responsive genes. In direct co-culture with cancer-associated fibroblast-like PShTert myofibroblasts, 10 nM DHT induced changes in the expression of androgen-responsive genes but did not inhibit proliferation.

Conclusions

This is the first study to show that EAC cell lines respond to androgen in vitro. Proliferation together with the expression of androgen-responsive genes was dependent on the concentration of DHT, or the presence of a permissive microenvironment, consistent with observations in the tissues. These findings are consistent with a role for androgen signaling in EAC.
Appendix
Available only for authorised users
Literature
2.
go back to reference Edgren G, Adami HO, Weiderpass E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013;62:1406–1414.CrossRefPubMed Edgren G, Adami HO, Weiderpass E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013;62:1406–1414.CrossRefPubMed
3.
go back to reference Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–1158.CrossRefPubMed Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–1158.CrossRefPubMed
4.
go back to reference Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232–248.CrossRefPubMed Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232–248.CrossRefPubMed
5.
go back to reference Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013;45:625–629.CrossRefPubMed Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013;45:625–629.CrossRefPubMed
6.
7.
go back to reference Oliver SE, Robertson CS, Logan RF. Oesophageal cancer: a population-based study of survival after treatment. Br J Surg. 1992;79:1321–1325.CrossRefPubMed Oliver SE, Robertson CS, Logan RF. Oesophageal cancer: a population-based study of survival after treatment. Br J Surg. 1992;79:1321–1325.CrossRefPubMed
8.
go back to reference Awan AK, Iftikhar SY, Morris TM, et al. Androgen receptors may act in a paracrine manner to regulate oesophageal adenocarcinoma growth. Eur J Surg Oncol. 2007;33:561–568.CrossRefPubMed Awan AK, Iftikhar SY, Morris TM, et al. Androgen receptors may act in a paracrine manner to regulate oesophageal adenocarcinoma growth. Eur J Surg Oncol. 2007;33:561–568.CrossRefPubMed
9.
go back to reference Cooper SC, Trudgill NJ. Subjects with prostate cancer are less likely to develop esophageal cancer: analysis of SEER 9 registries database. Cancer Causes Control. 2012;23:819–825.CrossRefPubMed Cooper SC, Trudgill NJ. Subjects with prostate cancer are less likely to develop esophageal cancer: analysis of SEER 9 registries database. Cancer Causes Control. 2012;23:819–825.CrossRefPubMed
10.
go back to reference Rutegard M, Lagergren P, Nordenstedt H, Lagergren J. Oesophageal adenocarcinoma: the new epidemic in men? Maturitas. 2011;69:244–248.CrossRefPubMed Rutegard M, Lagergren P, Nordenstedt H, Lagergren J. Oesophageal adenocarcinoma: the new epidemic in men? Maturitas. 2011;69:244–248.CrossRefPubMed
11.
12.
go back to reference van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. Age and sex distribution of the incidence of Barrett’s esophagus found in a Dutch primary care population. Am J Gastroenterol. 2005;100:2599–2600.CrossRefPubMed van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. Age and sex distribution of the incidence of Barrett’s esophagus found in a Dutch primary care population. Am J Gastroenterol. 2005;100:2599–2600.CrossRefPubMed
13.
go back to reference Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58:16–23.CrossRefPubMed Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58:16–23.CrossRefPubMed
14.
go back to reference Leach DA, Powell SM, Bevan CL. Women in cancer thematic review: new roles for nuclear receptors in prostate cancer. Endocr Relat Cancer. 2016;23:T85–T108.CrossRefPubMed Leach DA, Powell SM, Bevan CL. Women in cancer thematic review: new roles for nuclear receptors in prostate cancer. Endocr Relat Cancer. 2016;23:T85–T108.CrossRefPubMed
15.
go back to reference Smith E, Palethorpe HM, Ruszkiewicz AR, et al. Androgen receptor and androgen-responsive gene FKBP5 are independent prognostic indicators for esophageal adenocarcinoma. Dig Dis Sci. 2016;61:433–443.CrossRefPubMed Smith E, Palethorpe HM, Ruszkiewicz AR, et al. Androgen receptor and androgen-responsive gene FKBP5 are independent prognostic indicators for esophageal adenocarcinoma. Dig Dis Sci. 2016;61:433–443.CrossRefPubMed
16.
go back to reference Smith E, Ruszkiewicz AR, Jamieson GG, Drew PA. IGFBP7 is associated with poor prognosis in oesophageal adenocarcinoma and is regulated by promoter DNA methylation. Br J Cancer. 2014;110:775–782.CrossRefPubMed Smith E, Ruszkiewicz AR, Jamieson GG, Drew PA. IGFBP7 is associated with poor prognosis in oesophageal adenocarcinoma and is regulated by promoter DNA methylation. Br J Cancer. 2014;110:775–782.CrossRefPubMed
17.
go back to reference Abu-Sneineh A, Tam W, Schoeman M, et al. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett’s oesophagus. Aliment Pharmacol Ther. 2010;32:1023–1030.CrossRefPubMed Abu-Sneineh A, Tam W, Schoeman M, et al. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett’s oesophagus. Aliment Pharmacol Ther. 2010;32:1023–1030.CrossRefPubMed
18.
go back to reference Alvarez H, Koorstra JB, Hong SM, et al. Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line. Cancer Biol Ther. 2008;7:1753–1755.CrossRefPubMedPubMedCentral Alvarez H, Koorstra JB, Hong SM, et al. Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line. Cancer Biol Ther. 2008;7:1753–1755.CrossRefPubMedPubMedCentral
19.
go back to reference Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer. 1997;75:258–263.CrossRefPubMedPubMedCentral Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer. 1997;75:258–263.CrossRefPubMedPubMedCentral
20.
go back to reference Li Y, Li CX, Ye H, et al. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med. 2008;12:2790–2798.CrossRefPubMedPubMedCentral Li Y, Li CX, Ye H, et al. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med. 2008;12:2790–2798.CrossRefPubMedPubMedCentral
21.
go back to reference Leach DA, Need EF, Toivanen R, et al. Erratum: Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget. 2015;6:36923.CrossRefPubMedPubMedCentral Leach DA, Need EF, Toivanen R, et al. Erratum: Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget. 2015;6:36923.CrossRefPubMedPubMedCentral
22.
go back to reference Leach DA, Need EF, Toivanen R, et al. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget. 2015;6:16135–16150.CrossRefPubMedPubMedCentral Leach DA, Need EF, Toivanen R, et al. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget. 2015;6:16135–16150.CrossRefPubMedPubMedCentral
23.
go back to reference Dobrenkov K, Olszewska M, Likar Y, et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med. 2008;49:1162–1170.CrossRefPubMedPubMedCentral Dobrenkov K, Olszewska M, Likar Y, et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med. 2008;49:1162–1170.CrossRefPubMedPubMedCentral
24.
go back to reference Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198–213.CrossRefPubMed Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198–213.CrossRefPubMed
25.
go back to reference Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002;16:113–120.CrossRefPubMed Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002;16:113–120.CrossRefPubMed
26.
go back to reference Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997;138:1406–1412.CrossRefPubMed Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997;138:1406–1412.CrossRefPubMed
27.
go back to reference Kokontis JM, Lin HP, Jiang SS, et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2. PLoS ONE. 2014;9:e109170.CrossRefPubMedPubMedCentral Kokontis JM, Lin HP, Jiang SS, et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2. PLoS ONE. 2014;9:e109170.CrossRefPubMedPubMedCentral
28.
go back to reference Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res. 1993;53:1304–1311.PubMed Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res. 1993;53:1304–1311.PubMed
29.
go back to reference Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol. 1997;126:59–73.CrossRefPubMed Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol. 1997;126:59–73.CrossRefPubMed
30.
go back to reference Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate. 2006;66:1329–1338.CrossRefPubMed Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate. 2006;66:1329–1338.CrossRefPubMed
31.
go back to reference Marcelli M, Haidacher SJ, Plymate SR, Birnbaum RS. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology. 1995;136:1040–1048.CrossRefPubMed Marcelli M, Haidacher SJ, Plymate SR, Birnbaum RS. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology. 1995;136:1040–1048.CrossRefPubMed
32.
go back to reference Shen R, Sumitomo M, Dai J, et al. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology. 2000;141:1699–1704.CrossRefPubMed Shen R, Sumitomo M, Dai J, et al. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology. 2000;141:1699–1704.CrossRefPubMed
33.
go back to reference Chauhan S, Kunz S, Davis K, et al. Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells: role of RhoB signaling. J Biol Chem. 2004;279:937–944.CrossRefPubMed Chauhan S, Kunz S, Davis K, et al. Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells: role of RhoB signaling. J Biol Chem. 2004;279:937–944.CrossRefPubMed
34.
go back to reference Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995;52:459–467.CrossRefPubMed Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995;52:459–467.CrossRefPubMed
35.
go back to reference Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006;66:7775–7782.CrossRefPubMed Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006;66:7775–7782.CrossRefPubMed
36.
go back to reference Rossi R, Franceschetti P, Maestri I, et al. Evidence for androgen receptor gene expression in human thyroid cells and tumours. J Endocrinol. 1996;148:77–85.CrossRefPubMed Rossi R, Franceschetti P, Maestri I, et al. Evidence for androgen receptor gene expression in human thyroid cells and tumours. J Endocrinol. 1996;148:77–85.CrossRefPubMed
37.
go back to reference Rossi R, Zatelli MC, Franceschetti P, et al. Inhibitory effect of dihydrotestosterone on human thyroid cell growth. J Endocrinol. 1996;151:185–194.CrossRefPubMed Rossi R, Zatelli MC, Franceschetti P, et al. Inhibitory effect of dihydrotestosterone on human thyroid cell growth. J Endocrinol. 1996;151:185–194.CrossRefPubMed
38.
go back to reference Vander Griend DJ, Litvinov IV, Isaacs JT. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci. 2014;10:627–642.CrossRefPubMedPubMedCentral Vander Griend DJ, Litvinov IV, Isaacs JT. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci. 2014;10:627–642.CrossRefPubMedPubMedCentral
39.
go back to reference Antony L, van der Schoor F, Dalrymple SL, Isaacs JT. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/beta-catenin/TCF-4 complex inhibition of c-MYC transcription. Prostate. 2014;74:1118–1131.CrossRefPubMedPubMedCentral Antony L, van der Schoor F, Dalrymple SL, Isaacs JT. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/beta-catenin/TCF-4 complex inhibition of c-MYC transcription. Prostate. 2014;74:1118–1131.CrossRefPubMedPubMedCentral
40.
go back to reference Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL. Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ. 2002;13:1–11.PubMed Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL. Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ. 2002;13:1–11.PubMed
41.
go back to reference Yu SQ, Lai KP, Xia SJ, Chang HC, Chang C, Yeh S. The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl. 2009;11:39–48.CrossRefPubMed Yu SQ, Lai KP, Xia SJ, Chang HC, Chang C, Yeh S. The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl. 2009;11:39–48.CrossRefPubMed
43.
go back to reference Banu KS, Govindarajulu P, Aruldhas MM. Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. Endocr Pathol.. 2001;12:315–327.CrossRefPubMed Banu KS, Govindarajulu P, Aruldhas MM. Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. Endocr Pathol.. 2001;12:315–327.CrossRefPubMed
45.
go back to reference Roediger J, Hessenkemper W, Bartsch S, et al. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer. 2014;13:214.CrossRefPubMedPubMedCentral Roediger J, Hessenkemper W, Bartsch S, et al. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer. 2014;13:214.CrossRefPubMedPubMedCentral
46.
go back to reference Shao C, Wang Y, Yue HH, et al. Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. J Androl. 2007;28:804–812.CrossRefPubMed Shao C, Wang Y, Yue HH, et al. Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. J Androl. 2007;28:804–812.CrossRefPubMed
47.
go back to reference Rossi R, Zatelli MC, Valentini A, et al. Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. J Endocrinol. 1998;159:373–380.CrossRefPubMed Rossi R, Zatelli MC, Valentini A, et al. Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. J Endocrinol. 1998;159:373–380.CrossRefPubMed
48.
go back to reference Castoria G, Giovannelli P, Di Donato M, et al. Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells. Cell Death Dis. 2014;5:e1548.CrossRefPubMedPubMedCentral Castoria G, Giovannelli P, Di Donato M, et al. Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells. Cell Death Dis. 2014;5:e1548.CrossRefPubMedPubMedCentral
49.
50.
go back to reference Leach DA, Need EF, Trotta AP, Grubisha MJ, DeFranco DB, Buchanan G. Hic-5 influences genomic and non-genomic actions of the androgen receptor in prostate myofibroblasts. Mol Cell Endocrinol. 2014;384:185–199.CrossRefPubMed Leach DA, Need EF, Trotta AP, Grubisha MJ, DeFranco DB, Buchanan G. Hic-5 influences genomic and non-genomic actions of the androgen receptor in prostate myofibroblasts. Mol Cell Endocrinol. 2014;384:185–199.CrossRefPubMed
51.
go back to reference Leach DA, Trotta AP, Need EF, Risbridger GP, Taylor RA, Buchanan G. The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome. Prostate. 2017;77:185–195.CrossRefPubMed Leach DA, Trotta AP, Need EF, Risbridger GP, Taylor RA, Buchanan G. The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome. Prostate. 2017;77:185–195.CrossRefPubMed
52.
go back to reference Lai KP, Huang CK, Fang LY, et al. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH). Mol Endocrinol. 2013;27:1617–1631.CrossRefPubMedPubMedCentral Lai KP, Huang CK, Fang LY, et al. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH). Mol Endocrinol. 2013;27:1617–1631.CrossRefPubMedPubMedCentral
53.
go back to reference Li Y, Zhang DY, Ren Q, et al. Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching. Mol Cell Biol. 2012;32:2454–2466.CrossRefPubMedPubMedCentral Li Y, Zhang DY, Ren Q, et al. Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching. Mol Cell Biol. 2012;32:2454–2466.CrossRefPubMedPubMedCentral
Metadata
Title
Androgen Signaling in Esophageal Adenocarcinoma Cell Lines In Vitro
Authors
Helen M. Palethorpe
Paul A. Drew
Eric Smith
Publication date
01-12-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4794-5

Other articles of this Issue 12/2017

Digestive Diseases and Sciences 12/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.